Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes. The albumin-bilirubin (ALBI) grade is a validated index of liver function in patients with HCC.
SUMMARY Background
Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes. The albumin-bilirubin (ALBI) grade is a validated index of liver function in patients with HCC.
Aim
To test the accuracy of the ALBI grade in predicting post-sorafenib overall survival (PSOS) in patients who permanently discontinued treatment.
Methods
From a prospectively maintained international database of 447 consecutive referrals, we derived 386 eligible patients treated with sorafenib within Barcelona Clinic Liver Cancer C stage (62%), 75% of whom were of Child class A at initiation. Clinical variables at sorafenib discontinuation were analysed for their impact on post-sorafenib overall survival using uni-and multivariable analyses.
INTRODUCTION
In patients with hepatocellular carcinoma (HCC), liver cirrhosis carries an independent clinical course from that of neoplastic disease progression 1 and often represents a barrier to the provision of active anti-cancer treatment. 2 This is particularly true in the more advanced stages of the disease, where liver dysfunction together with deteriorating performance status (PS) 3 remain the strongest adverse prognostic factors. 4, 5 Sorafenib remains the only first-line treatment option of proven survival benefit in advanced HCC. 6, 7 However, depth and length of response to sorafenib are modest, with <2% objective response rates. Even in patients who achieve initial disease control, progression inexorably occurs within a median interval of 3 months. 8 Pre-registrative clinical trials of sorafenib in HCC were originally conducted in highly selected populations, as evidenced by high screening failure rates approaching 30%. 6 Whilst clinically developed in patients with optimal liver function, subsequent implementation of sorafenib in routine practice to include subjects with a wider variation in hepatic reserve and PS has highlighted numerous challenges in the clinical management of these patients. 9 In the clinic, neoplastic disease progression, deteriorating PS, hepatic decompensation or unacceptable treatment-related toxicity are the leading causes of permanent sorafenib discontinuation. 10, 11 At treatment cessation, the majority of patients will only qualify for best supportive care, whereas a smaller proportion might be suitable for second-line therapies, an area that is currently at the focus of intense clinical research efforts.
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Adequate hepatic function is a universal pre-requisite to access experimental therapies. However, it has been recently suggested that the prognostic ability of the Child class, the scoring system traditionally employed to evaluate liver function based on five parameters, might be outclassed by a novel, more objective biochemical nomogram solely composed of serum albumin and bilirubin, the ALBI grade. 13 The improved clinical utility of this score stems from its ability to further dissect patient groups with different survival outcomes within each Child functional class 14 as well as Barcelona Clinic Liver
Cancer (BCLC) stage of HCC. 15 More accurate prognostic predictors of liver functional reserve are highly required in patients who fail sorafenib treatment, given that a proportion of patients might be eligible for further lines of anti-cancer treatment in an experimental setting. Whilst previous studies have focused on the radiological pattern of progression on sorafenib as a predictor of survival, this trait, while biologically important and potentially useful as a stratification factor in second-line studies, does not influence patients' eligibility to further lines of therapy, for which the main barriers are represented by progression to terminal-stage disease either due to worsening PS or liver decompensation. 16 Furthermore, as an improved marker of functional reserve, the ALBI grade might be useful to facilitate patient stratification according to their risk of toxicity from systemic anti-cancer treatment, a non-negligible concern in patients with underlying impairment of hepatic drug clearance. 17 We therefore conducted a study to ascertain the prognostic value of the ALBI grade in patients who permanently discontinued sorafenib treatment in a large collaborative study including patients from Europe, and Asia.
PATIENTS AND METHODS
The study population derives from a prospectively maintained, multi-centre patient dataset including 447 consecutive patients treated with sorafenib between 2008 and 2015 within an international research consortium. We excluded 30 patients who were on sorafenib and further 39 due to incomplete data ( Figure 1 ). The final dataset (n = 386) comprised 191 patients from three European institutions including 76 (20%) treated at Imperial College London (UK), 44 (11%) from the Academic Liver Unit in Novara (Italy) and 71 patients (18%) treated at the University Hospital in Freiburg (Germany). These patients were incorporated into a larger dataset of 195 subjects (51%) with similar features treated at the Kindai University Faculty of Medicine in Osaka (Japan).
The primary aim was to evaluate the ALBI grade as a predictor of post-sorafenib overall survival (PSOS) and verify its accuracy in comparison with Child class. PSOS was calculated from the time of sorafenib discontinuation to the time of death/last-documented follow-up. Post-sorafenib treatment status was documented for all patients.
The ALBI was calculated using the formula: linear predictor = (log 10 bilirubin 9 0.66) + (albumin 9 À0.085), where bilirubin is expressed in lmol/L and albumin in g/ L. Patients were categorised as ALBI grade 1 if the linear predictor ≤À2.60; ALBI grade 2 if more than À2.60 to ≤À1.39 and ALBI grade 3 if >À1.39.
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All patients were diagnosed with HCC in accordance to international guidelines. 18 Sorafenib was administered in accordance to the BCLC treatment algorithm to stage C patients or earlier if, on the basis of a multi-disciplinary discussion, they were deemed unfit for or had failed prior loco-regional therapies. Routine clinical reviews during sorafenib therapy were performed at each cycle of treatment and included physical examination, blood test review and adverse events evaluation. Reporting of sorafenib-related AEs followed NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.
19
Clinical data at sorafenib commencement and discontinuation included complete blood count, liver function tests, alpha-fetoprotein (AFP) levels and the international normalised ratio value for prothrombin time. Radiological staging of the disease was performed using computerised tomography (CT) and/or magnetic resonance imaging as clinically required. Computation of the ALBI grade, 13 Child functional class and BCLC stage followed standard pre-published methodology. 20 Periodic restaging using triple-phase CT during sorafenib treatment was performed at 8-12 weekly intervals. 21 Reasons for permanent sorafenib cessation included disease progression, unacceptable toxicity defined by grade 2-4 AEs not responding to dose reductions and/or temporary sorafenib discontinuation. In patients with multiple causes for treatment discontinuation (i.e. liver decompensation or unacceptable toxicity), tumour progression was considered the primary cause if confirmed radiologically. 10 The study was conducted in accordance to Good Clinical Practice standards following the ethical guidelines published in the Declaration of Helsinki.
Statistical analysis Univariable analysis survival followed Kaplan-Meier methodology and log-rank statistics. Cox proportional hazards regression models were for multivariable analyses of survival, following formal assessment of the proportional-hazard assumption for each variable using log-likelihood ratio tests over time. 22 Receiver operating characteristic (ROC) methodology was used to test the accuracy of the candidate biomarkers in predicting 90-days mortality. 23 Harrell's concordance index method (cindex) was used to rank the different staging systems according to their capacity of discriminating patients according to outcome. Where we assessed the predictive ability of a Cox proportional hazards model, we compared the actual survival outcomes of usable pairs of patients with the values of their estimated prognostic indices from the Cox model. Where the assessment of prediction of multiple biomarkers was performed, the cindex was adjusted within the R package for the overoptimism produced by modelling, and assessment being done on the same data via comparison with 150 bootstrap samples. For all analyses, a P ≤ 0.05 was considered statistically significant. Statistical analyses were performed using SPSS package version 20.0 (IBM Inc., Chicago, IL, USA) and R Statistical Computing Environment (R Foundation, Vienna, Austria).
RESULTS

Patient characteristics
Patient features are presented in Table 1 . The majority of patients were of BCLC-C stage (n = 248, 62%). The predominant aetiological factors of chronic liver disease were HCV infection (n = 150, 39%), HBV infection (n = 62, 16%) and alcohol excess (n = 72, 19%). In total, 290 patients (75%) Child class A at sorafenib initiation, whereas 96 (25%) were of Child B class. All patients had a PS ≤ 1 at sorafenib initiation. Sorafenib discontinuation followed primarily progression of disease in 263 patients (64%), followed by unacceptable toxicity in 91 (24%).
The most common sorafenib-related AEs occurring at any grade during treatment were diarrhoea (n = 143, 37%), palmo-plantar erythrodysesthaesia (PPE) (n = 139, 36%) and fatigue (n = 88, 22%). Similarly, when considering AEs ≥Grade 2, PPE was the most prevalent (n = 33, 9%) followed by diarrhoea (n = 24, 6%) and fatigue (n = 21, 5%). In total 196 patients (51%) had experienced at least 1 Grade 2 AE during sorafenib treatment, whereas 104 (27%) had experienced at least 1 Grade 3 AE. Toxicity prompted permanent sorafenib dose reductions in 59 patients (15%). At the time of sorafenib discontinuation, the stage-distribution according to BCLC had significantly changed compared to baseline, with the majority of patients clustering within BCLC-C criteria (n = 189, 49%) followed by BCLC-B (n = 105, 27%) and D (n = 92, 24%). Stage migration to BCLC-D derived from progression to Child class to C in 39 patients (10%) and worsening PS to >2 in 53 patients (14%). Following sorafenib discontinuation, the majority of patients received best supportive care (n = 294, 76%). Of the 92 patients (24%) who received further active treatment, 24 (6%) received >1 line of therapy.
Post-sorafenib overall survival
At the time of analysis (April 2016), there were 298 deaths (77%). Patients were followed up for a median of 13 months (range 1-70 months). Median duration of treatment was 2.9 months (range 1-53 months). Median OS from the time of sorafenib initiation was 9.4 months (95% CI 7.6-11.0), whereas median PSOS was 3 ) and 1.6 of grade 3 (n = 188, 1.0-2.0; log-rank P < 0.001). The HR between ALBI 2 and 1 was 1.7 (95% CI 1.1-2.9) and between ALBI 3 and ALBI 1 was 4.1 (95% CI 2.5-6.8) (Figure 2a ). Child classification was derived in 377 patients (98%). Child class was associated with post-sorafenib survival with median OS of 8.2 months (95% CI 5.2-11) for Child A (n = 160), 2.1 months (95% CI 1.6-2.6) for Child B (n = 178) and 1 month for Child C patients (n = 39, 95% CI 0.5-1.3, log-rank P < 0.001; Figure 2b ). The HR between Child class B and A was 2.4 (95% CI 1.8-3.1) and between Child C and A was 4.7 (95% CI 3.0-7.2). A comparison of ALBI grade and Child class for the 377 patients with both scores available is reported in Table S1 .
We further investigated the prognostic relationship between ALBI and Child class by evaluating the stratifying potential of the ALBI across each Child class. The analysis was limited to Child A and B classes because the entire patients with Child C were co-classified as ALBI Grade 3. As shown in Table S2 , the ALBI could sub-classify patients within Child A according to significantly different survival times ranging from a median OS of 17.5-1.0 months across the three ALBI grades. This was not replicated in Child B patients where the ALBI was not prognostic.
We performed further subgroup analyses by excluding patients who, according to current guidelines, displayed untreatable disease progression at sorafenib discontinuation (i.e. patients migrating to BCLC-D stage, n = 92, 24%). In a subset of 294 potential candidates for secondline therapies, the ALBI grade was predictive of survival with median OS of 17.5 months (95% HR 9.0-26) for ALBI 1 (n = 24), 7.5 months for ALBI 2 (95% CI 5.4-9.5) Figure 2 | Kaplan-Meier curves describing the overall survival of patients with HCC (n = 386) at sorafenib discontinuation categorised according to albuminbilirubin (ALBI) grade (a) and Child class (b). and 1.9 months for ALBI 3 (95% CI 1.4-2.4; log-rank P < 0.001; Figure 3a) . Similarly, patients with Child class A (n = 135) had better median OS at 10 months (95% CI 7-13) compared to Child B (n = 153) whose median OS was 2.2 (95% CI 1.6-2.8) (Figure 3b ).
In the same subset of 294 patients, we comparatively tested ALBI grade and Child class for their independent predictive role in estimating PSOS. We tested ALBI and Child class in concurrent, multivariable Cox regression models adjusted for the confounding effect of BCLC stage at discontinuation and subsequent treatment. Multivariable analysis of survival confirmed both ALBI and Child class as independent predictors of PSOS ( Table 2) .
As shown in Figure 4 ROC curve analysis confirmed optimal prognostic accuracy of both ALBI and Child class in predicting 90-days mortality rates, where the ALBI grade displayed better accuracy with an area under the ROC curve (AUROC) of 0.69 (95% CI 0.63-0.75) over Child class 0.66 (0.59-0.72; P < 0.001).
We compared the predictive ability of ALBI and Child class in estimating PSOS using Harrel's c-index. In the whole study population (n = 386), ALBI was superior to Child class (c-index 0.64 vs. 0.62). ALBI displayed highest accuracy in patients considered eligible to second-line therapies (n = 294) (c-index 0.65 vs. 0.63 for Child class), whereas both scores had significantly lower accuracy in patients experiencing untreatable disease progression (n = 92) (c-index 0.54 for ALBI and 0.53 for Child class).
DISCUSSION
The provision of safe and effective systemic anti-cancer treatment in patients with HCC has been traditionally hindered by the concurrent presence of liver dysfunction, which imposes a significant toll on patients' survival and ability to tolerate systemic therapies. 24 In the drug development process, cirrhosis limits enrolment of patients with HCC to early phase clinical trials due to safety concerns stemming from liver dysfunction, reducing the detection of early efficacy signals from novel investigational medicinal products. In later stage trials where treatment efficacy testing is powered on survival benefit, liver dysfunction is a major confounder in influencing the mortality of patients with advanced HCC independently from the progression of malignancy. 25 Such confounding role has affected the clinical development of sorafenib, where unsurprisingly, despite homogeneity in screening criteria and treatment schedules, patients enrolled into the SHARP and Asian Pacific trials had different survival, suggesting that subtle variations in liver function might have at least in part accounted for the observed heterogeneity in trial outcomes. 6, 7 Accumulating evidence suggests the ALBI grade as a more accurate predictor of liver functional reserve across the various stages of HCC compared to standard Child classification, 13, 14 including patients with advanced HCC. 26, 27 In our multi-institutional study including a large cohort of patients treated with sorafenib, we demonstrated for the first time the independent prognostic ability of the ALBI in predicting PSOS. In unselected patients who failed sorafenib therapy, the ALBI grade calculated at the moment of permanent sorafenib discontinuation was capable of differentiating patient subgroups with up to a 3-fold difference in median survival times across the diverse strata. Interestingly, the prognostic accuracy of the ALBI was preserved following exclusion of patients who, based on BCLC stage at sorafenib withdrawal, were unfit for second-line therapies. An even stronger and clinically important stratifying potential of the ALBI grade transpired by restricting our analysis of survival to patients in Child A functional class, in whom preservation of an ALBI grade 1 at treatment discontinuation predicted for median survival times in excess of 17 months, reducing to 8 months for ALBI grade 2.
It has been suggested that the improved accuracy of ALBI, especially within Child A criteria, is secondary to the modification of pre-defined cut-off points for albumin and bilirubin, which might allow clinicians to capture more subtle differences in the biosynthetic function of the cirrhotic liver. [27] [28] [29] Certainly, abandoning scoring of encephalopathy, ascites or coagulopathy, two of which require subjective assessments, does not reduce the accuracy of the ALBI in predicting survival nor 90-days mortality rates, a landmark survival endpoint that investigators often use to assess the suitability of patients to clinical trials. Interestingly, whilst 92% of ALBI grade 1 patients satisfied Child A criteria, such proportion reduced to 73% in ALBI grade 2 patients and 3% in ALBI grade 3, suggesting a potentially higher prognostic heterogeneity in grade 2 patients due to the contribution of diverse functional subclasses. 30 This is not the first study to highlight, amongst other factors, the key role of deteriorating liver function as a predictor of survival in patients with advanced HCC who might be otherwise fit for second-line therapies. The role of Child class deterioration was reported by Reig et al., although survival analysis was limited to only 85 patients, who had all discontinued sorafenib due to disease progression. 16 Likewise, despite not having directly tested Child class, Iavarone and colleagues provide convincing confirmation of the adverse prognostic role of a composite panel of individual biomarkers of impaired liver function including albumin, bilirubin, prothrombin time as well as clinically overt hepatic decompensation as predictors of mortality. 10 Based on our data, the maximal improvement in prognostication conferred by the ALBI grade is evident in patients who fulfil Child A criteria, a point which may limit the applicability of this score in patients with intermediate to advanced liver dysfunction. In contrast to the previous studies, we prospectively followed up a larger, multi-institutional cohort of patients from Europe and Asia, to control for the heterogeneity in survival generated by varying aetiological factors and tumour burden. In addition, our analysis of survival is also controlled for post-progression treatment status, an established confounder in estimating OS not taken into account in previous studies. These methodological strengths allow our observation to be controlled for a number of important sources of systematic bias, suggesting that the independent prognostic value of the ALBI is a true finding and generalisable to patients of diverse geographical origin, ethnicity and aetiology. 31 In conclusion, this study validates the ALBI grade as a prognostic index in HCC patients who permanently discontinued sorafenib. The increased accuracy of the ALBI comes at no additional costs, as it relies on routinely available, objective biochemical indices. Due to limited evidence-based treatment options in patients who fail sorafenib, 32 the enhanced discriminative power of the ALBI in advanced HCC is particularly important for optimal patient stratification, especially in suitable candidates for clinical trials. 33 The accurate definition of patient subpopulations with prolonged stability in liver functional reserve might enhance efficacy testing in phase II-III trials by reducing the heterogeneity stemming from concomitant liver failure. 12 This is particularly important in trial design, where inaccurate assumptions over predicted survival times in placebo group as well as the choice of pre-planned stratification factors has been a problematic issue in the development of molecularly targeted therapies in the second-line setting. 34 Secondly, improved hepatic reserve phenotyping might help mitigating the risks stemming from systemic toxicity, a nontrivial issue in patients with HCC where treatment discontinuation due to AEs is higher than other malignancies, 35 and has in the past led to the premature termination of development of sunitinib due to concerns over excessive mortality in the treatment arm. Although exploring the relationship between ALBI grade and toxicity from systemic treatment was beyond the aims of our study, this should be formally evaluated in future prospective trials.
Although the relatively limited sample size is a potential limitation to our study, the survival times and clinicopathological features describing our cohort are similar to previous studies to suggest our results are generalisable to the broader population of patients with HCC who fail sorafenib therapy. 10, 16, 36 Moreover, the choice of evaluating this score in a large, multi-institutional patient dataset limits the chances of selection bias.
In the absence of convincingly robust molecular biomarkers to dissect the biological heterogeneity of advanced HCC, our study is the first to support the use of the ALBI as an accurate, objective and reproducible marker of liver function in HCC. The prognostic relationship between ALBI and survival in patients should be further defined in independent studies in a view to facilitate the full clinical implementation of this promising biomarker.
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